Dr Klaus Okkenhaug

Dr Okkenhaug obtained his BSc in Biochemistry from the University of Victoria and his PhD in Immunology from the University of Toronto, where he studied CD28 signalling. He subsequently joined Bart Vanhaesebroeck's group in 1999, working on the role p110δ in immune responses, before moving to the Babraham Institute, Cambridge, as a Group Leader in 2003, where he currently is a Wellcome Trust New Investigator. His group investigates the role of cell signalling pathways in the immune system, with particular focus on PI3Ks.